JP2013067635A5 - - Google Patents

Download PDF

Info

Publication number
JP2013067635A5
JP2013067635A5 JP2012255810A JP2012255810A JP2013067635A5 JP 2013067635 A5 JP2013067635 A5 JP 2013067635A5 JP 2012255810 A JP2012255810 A JP 2012255810A JP 2012255810 A JP2012255810 A JP 2012255810A JP 2013067635 A5 JP2013067635 A5 JP 2013067635A5
Authority
JP
Japan
Prior art keywords
group
concentration
enhancing polymer
surfactants
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012255810A
Other languages
English (en)
Japanese (ja)
Other versions
JP5648038B2 (ja
JP2013067635A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013067635A publication Critical patent/JP2013067635A/ja
Publication of JP2013067635A5 publication Critical patent/JP2013067635A5/ja
Application granted granted Critical
Publication of JP5648038B2 publication Critical patent/JP5648038B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012255810A 2006-02-09 2012-11-22 Cetp阻害剤のポリマー製剤 Expired - Fee Related JP5648038B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77178206P 2006-02-09 2006-02-09
US60/771,782 2006-02-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008554428A Division JP5773560B2 (ja) 2006-02-09 2007-02-09 Cetp阻害剤のポリマー製剤

Publications (3)

Publication Number Publication Date
JP2013067635A JP2013067635A (ja) 2013-04-18
JP2013067635A5 true JP2013067635A5 (https=) 2013-09-05
JP5648038B2 JP5648038B2 (ja) 2015-01-07

Family

ID=38198472

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008554428A Expired - Fee Related JP5773560B2 (ja) 2006-02-09 2007-02-09 Cetp阻害剤のポリマー製剤
JP2012255810A Expired - Fee Related JP5648038B2 (ja) 2006-02-09 2012-11-22 Cetp阻害剤のポリマー製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008554428A Expired - Fee Related JP5773560B2 (ja) 2006-02-09 2007-02-09 Cetp阻害剤のポリマー製剤

Country Status (14)

Country Link
US (1) US8030359B2 (https=)
EP (1) EP1983966B1 (https=)
JP (2) JP5773560B2 (https=)
KR (1) KR101418267B1 (https=)
CN (2) CN103735515A (https=)
AU (1) AU2007212197B2 (https=)
BR (1) BRPI0707584A2 (https=)
CA (1) CA2641451C (https=)
IL (1) IL192977A (https=)
NO (1) NO341326B1 (https=)
NZ (1) NZ569700A (https=)
RU (1) RU2457841C2 (https=)
WO (1) WO2007092642A2 (https=)
ZA (1) ZA200805854B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085996A2 (en) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
PE20091041A1 (es) * 2007-10-19 2009-08-22 Abbott Gmbh & Co Kg Producto de dispersion solida que contiene un compuesto a base de n-aril urea
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体アンタゴニスト
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
NZ610638A (en) * 2010-11-24 2015-05-29 Melinta Therapeutics Inc Pharmaceutical compositions comprising radezolid
SG10201605304VA (en) * 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
WO2013181174A2 (en) * 2012-05-31 2013-12-05 Merck Sharp & Dohme Corp. Solid dosage formulations of an orexin receptor antagonist
US9962446B2 (en) * 2012-07-17 2018-05-08 Dow Global Technologies Llc Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
CN104684545B (zh) * 2012-09-27 2018-04-03 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
WO2014076568A2 (en) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
RU2661399C1 (ru) * 2013-11-22 2018-07-16 Мерк Шарп И Доум Корп. Композиция ненуклеозидного ингибитора обратной транскриптазы
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RU2019123406A (ru) * 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
JPWO2016084949A1 (ja) * 2014-11-28 2017-09-07 興和株式会社 医薬
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN111803632B (zh) * 2019-04-09 2022-04-29 北京五和博澳药业股份有限公司 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途
PL3965739T3 (pl) * 2019-04-12 2025-01-13 Oblita Therapeutics Bvba Postacie dawkowane będące tabletkami oleilofosfocholiny
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
BR0210520A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
CN100410236C (zh) 2002-01-29 2008-08-13 雪兰诺实验室有限公司 作为蛋白酪氨酸磷酸酶调节剂的取代亚甲基酰胺衍生物
CN1625397A (zh) * 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
PT1603553E (pt) 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
US20070043079A1 (en) 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
CN102757397A (zh) * 2005-07-01 2012-10-31 默沙东公司 合成cetp抑制剂的方法
US8486983B2 (en) 2005-12-05 2013-07-16 Merck Sharp & Dohme Corp. Self-emulsifying formulations of CETP inhibitors

Similar Documents

Publication Publication Date Title
JP2013067635A5 (https=)
RU2014152031A (ru) Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
JP2011225578A5 (https=)
JP2014532638A5 (https=)
JP2013515742A5 (https=)
CN110248926A (zh) Lsd1抑制剂及其制备方法和应用
JP2012255026A5 (https=)
JP2014167026A5 (https=)
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
HRP20171512T1 (hr) Derivati betulina
MX2015012232A (es) Microesferas de buprenorfina de fuerte carga de medicamento y su metodo de fabricacion.
EP2760433A4 (en) PH-DEPENDENT SUPPORTS FOR THE TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINALTRAKTS, COMPOSITIONS, AND THEIR PREPARATION AND USE
JP2013529637A5 (https=)
AR102228A1 (es) Una formulación de metformina de liberación sostenida y un método de preparación de la misma
FR2963250B1 (fr) Emulsion de type huile dans l'eau sans tensioactif, son procede de preparation et ses utilisations
GEAP201814216A (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
ECSP15022442A (es) Producto de comicronización que comprende acetato de ulipristal
EA201500575A1 (ru) Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении
PH12014502609A1 (en) Mutilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
JOP20170197B1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول
JP2012051888A5 (https=)
IN2015DN01738A (https=)
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
JP2014508170A5 (https=)